Log in with your email address username.


[Correspondence] Denosumab and fracture risk in women with breast cancer

We read with great interest the report by Michael Gnant and colleagues1 about their randomised controlled trial of adjuvant denosumab for patients with breast cancer who are treated with aromatase inhibitors. Because of widespread concern about osteonecrosis of the jaw associated with the use of denosumab, this adverse event was carefully monitored during the trial. 31 suspected cases were adjudicated by an independent international expert panel, and no case met the diagnostic criteria of osteonecrosis of the jaw.